New RECIBM Criteria for Bone Metastases Match Existing Metrics and Reclassify 19% of Patients

Retrospective: RECIBM bone metastasis criteria had high agreement with MD Anderson, PERCIST, EORTC (κ=0.80–0.98) and reclassified 19% of 84 patients. Response was associated with OS (HR 0.07) and bone progression-free survival (HR 0.03).

• Retrospective study of 84 patients (median age 59, 59 male) with bone metastases evaluated by RECIBM, MD Anderson, PERCIST, and EORTC criteria.
• RECIBM showed highest C‑index for overall survival (0.807 vs 0.771–0.782) and bone progression‑free survival (0.849 vs 0.799–0.833), but differences were not significant after adjustment.
• Limitations: retrospective design, modest sample size, and lack of external validation; criteria were developed by consensus and tested on the same cohort.

RadPigeon summaries are original and for information only. They are not clinical advice.